<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718948</url>
  </required_header>
  <id_info>
    <org_study_id>17686_BIO</org_study_id>
    <nct_id>NCT04718948</nct_id>
  </id_info>
  <brief_title>Multimodal Spectroscopy to Detect Urothelial Cancer in Urine</brief_title>
  <official_title>&quot;The Feasibility of a Multimodal Spectroscopy Analysis to Detect Urothelial Cancer in Urine&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Laboratory for Non-Linear Spectroscopy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Careggi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To facilitate the follow-up of urothelial tumors and also make them more tolerable and less&#xD;
      invasive for patients, there is a minimally invasive and easy to perform examination which is&#xD;
      urinary cytology on 3 samples. This test is extremely specific, over 90% chance of cancer if&#xD;
      it is positive and is performed by expert cytopathologists, but it is burdened by a very low&#xD;
      sensitivity, which is especially acute in the case of low grade tumors. This makes it an&#xD;
      extremely useful test in case of positivity, but of little use if negative or doubtful, not&#xD;
      being able to consider it reliable.&#xD;
&#xD;
      To overcome this problem, our study aims to bring an approach based on a physical principle,&#xD;
      that is spectroscopy, which is fast non-invasive and does not require the use of additional&#xD;
      substances or contrast media in the diagnosis of urothelial neoplasms in samples of urine.&#xD;
&#xD;
      In our experience, multimodal optical fiber spectroscopy has proved extremely valid in&#xD;
      discriminating healthy urothelial tissue from tumor ex vivo, as well as providing important&#xD;
      information on the degree of urothelial neoplasia, with accuracy rates higher than 80%, for&#xD;
      which developed the idea of a technique based on multimodal spectroscopy.&#xD;
&#xD;
      If our method proves valid, it could improve the follow up and management of patients with&#xD;
      urothelial cancer, being able to support normal cytology and provide further support to the&#xD;
      cytopathologist, as well as simplify the diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Multimodal Spectroscopy Reliability</measure>
    <time_frame>Enrollment</time_frame>
    <description>Evaluate whether multimodal spectroscopy can discriminate between healthy controls and patients with urothelial neoplasia on urine, with an accuracy at least comparable to urinary cytology on 3 samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Multimodal Spectroscopy Grading</measure>
    <time_frame>Enrollment</time_frame>
    <description>Evaluate whether multimodal spectroscopy is able to discriminate between high or low grade urothelial lesions on urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Multimodal Spectroscopy Site Discrimination</measure>
    <time_frame>Enrollment</time_frame>
    <description>Evaluate whether multimodal spectroscopy is able to discriminate between lower or upper urinary tract lesions on urine</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Urinary Bladder Cancer</condition>
  <condition>Urinary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Patients Positive for Urinary Tract Cancer</arm_group_label>
    <description>Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention&#xD;
The group of cases will consist of patients who meet the inclusion and exclusion criteria in the operative note for:&#xD;
Transurethral Resection of Bladder Neoplasia (TURBT)&#xD;
Radical Cystectomy for Bladder Neoplasia&#xD;
Diagnostic ureterorenoscopy and / or laser treatment of ureteral and / or renal pelvis neoplasia&#xD;
Segmental ureterectomy with or without ureteral reimplantation&#xD;
Nephroureterectomy with or without bladder cuff excission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients Negative for Urinary Tract Cancer</arm_group_label>
    <description>Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention&#xD;
The control group will consist of patients who meet the inclusion and exclusion criteria in the operative note for:&#xD;
Transurethral Resection of Prostate (TURP)&#xD;
Other endoscopic treatments of Benign Prostatic Hyperplasia (BPH)&#xD;
Open interventions of prostatic adenomectomy&#xD;
Endoscopic lithotripsy interventions of bladder stones or cystotomy with removal of bladder stones&#xD;
Rigid and / or flexible ureterorenoscopy for the treatment of kidney and / or ureteral stones&#xD;
Placement of ureteral catheter for ureteral and / or renal stones&#xD;
Bladder Neck Incision (TUIP)&#xD;
Endoscopic urethrotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urinary Multimodal Fiber Optic Spectroscopy</intervention_name>
    <description>Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.&#xD;
It will be administered through a appositely designed device</description>
    <arm_group_label>Patients Negative for Urinary Tract Cancer</arm_group_label>
    <arm_group_label>Patients Positive for Urinary Tract Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine Cytology</intervention_name>
    <description>An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine</description>
    <arm_group_label>Patients Negative for Urinary Tract Cancer</arm_group_label>
    <arm_group_label>Patients Positive for Urinary Tract Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)</description>
    <arm_group_label>Patients Negative for Urinary Tract Cancer</arm_group_label>
    <arm_group_label>Patients Positive for Urinary Tract Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the inclusion and exclusion criteria will be enrolled at Urology ward&#xD;
        admission. Informed consent will be collected. Patients therapeutic routine will be&#xD;
        unaffected.&#xD;
&#xD;
        In the morning before surgery, the patient will collect urine sample. The patient will then&#xD;
        continue the previously established diagnostic therapeutic process. The sample will be&#xD;
        brought to the spectroscopic and cytological analysis. Samples will not be stored.&#xD;
&#xD;
        According to the sample size calculation based on the asymptotic normal distribution&#xD;
        theory, a total of 240 cases and 240 controls will be required if the study is to have 90%&#xD;
        power. A series of 5000 simulations generating binary test data with a true positive&#xD;
        frequency and a true negative frequency of 80% showed that these sample sizes produce 89%&#xD;
        power. Increasing the sample size to 250 cases and 250 controls increases the potency to&#xD;
        90%. Therefore, approximately 250 cases and 250 controls will be enrolled in this phase 2&#xD;
        validation study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        CASES Inclusion criteria&#xD;
&#xD;
        Patients over the age of 18 who are known for urological interventions for the following&#xD;
        pathologies will be considered for enrollment in the group of cases:&#xD;
&#xD;
          -  Bladder cancer&#xD;
&#xD;
          -  Urethral tumor&#xD;
&#xD;
          -  Renal Pelvis Tumor&#xD;
&#xD;
          -  Ureteral tumor&#xD;
&#xD;
        The exclusion criteria will be:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of informed consent&#xD;
&#xD;
          -  Persons with indwelling catheter&#xD;
&#xD;
          -  Presence of prostate cancer&#xD;
&#xD;
          -  Presence and / or history of renal cancer, except tumors of the renal pelvis&#xD;
&#xD;
        CHECKS Inclusion criteria&#xD;
&#xD;
        Patients over the age of 18 who are known for urological interventions for the following&#xD;
        pathologies will be considered for enrollment in the control group:&#xD;
&#xD;
          -  Kidney, ureteral or bladder stones&#xD;
&#xD;
          -  BPH&#xD;
&#xD;
        The exclusion criteria will be:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of informed consent&#xD;
&#xD;
          -  Indwelling Catheter wearers&#xD;
&#xD;
          -  Presence of prostate cancer&#xD;
&#xD;
          -  Presence of kidney cancer, including kidney pelvic tumors&#xD;
&#xD;
          -  Presence and / or history of ureteral cancer&#xD;
&#xD;
          -  Presence and / or history of bladder cancer&#xD;
&#xD;
          -  Presence and / or history of urethral cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Gacci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Baria, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Laboratory for Non-Linear Spectroscopy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Cicchi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Saverio Pavone, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Serni, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriella Nesi, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Morselli, MD</last_name>
    <phone>3473050852</phone>
    <phone_ext>+39</phone_ext>
    <email>simone.morselli.89@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Benemei, MD</last_name>
    <email>silvia.benemei@unifi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Morselli</last_name>
      <phone>3473050852</phone>
      <email>simone.morselli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alekseja Manera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Liaci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Gemma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Baria E, Morselli S, Anand S, Fantechi R, Nesi G, Gacci M, Carini M, Serni S, Cicchi R, Pavone FS. Label-free grading and staging of urothelial carcinoma through multimodal fibre-probe spectroscopy. J Biophotonics. 2019 Nov;12(11):e201900087. doi: 10.1002/jbio.201900087. Epub 2019 Aug 13.</citation>
    <PMID>31343832</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Simone Morselli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Urinary Tract Cancer</keyword>
  <keyword>Urine</keyword>
  <keyword>Spectroscopy</keyword>
  <keyword>Laser</keyword>
  <keyword>Urine Cytology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

